Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653847 · ClinicalTrials.gov registry record · NA
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT01653847 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 88 participants.
The verdict
NCT01653847, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
The immune system is the body's defense against infection and other disease. After transplantation, the body sees the new organ as "foreign" and tries to destroy or "reject" it. Immunosuppressive medications help to prevent the immune system from attacking a transplanted organ. The primary purpose of this study is to investigate the impact of two maintenance immunosuppressive regimens. Subjects who enroll in this study will be randomly selected to have tacrolimus and everolimus (group 1) or tacrolimus and mycophenolate mofetil (group 2) as their immunosuppression medication. This study will enroll adult patients who are scheduled to receive a kidney transplant. The study is designed to understand the mechanisms of Everolimus in regards to kidney function in transplant recipients. The investigators hypothesis is that decreased exposure to Tacrolimus to the immune system will then translate in better renal allograft function.
Interventions
- DRUG Tacrolimus with MMF
- DRUG Group 2: Tacrolimus with Everolimus.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-02 |
| Est. Completion | 2020-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01653847
The ClinicalTrials.gov registry entry for NCT01653847 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus with MMF is the first listed.
NCT01653847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01653847 about?
NCT01653847 is a clinical study titled "Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens". The immune system is the body's defense against infection and other disease. After transplantation, the body sees the new organ as "foreign" and tries to destroy or "reject" it. Immunosuppressive medications help to prevent the immune system from attacking a transplanted organ. The primary purpose o...
What is the current status of trial NCT01653847?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2013-02. Estimated completion is 2020-05.
What interventions are being tested in trial NCT01653847?
The interventions under investigation include: Tacrolimus with MMF (DRUG), Group 2: Tacrolimus with Everolimus. (DRUG).
Who is sponsoring clinical trial NCT01653847?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.